Clinical Cell Processing News – part 4, 2015

by Alexey Bersenev on August 6, 2015 · 0 comments

in clinical lab, notes, protocols

Post to Twitter Send Gmail Post to LinkedIn

Clinical Cell Processing News is a series about new protocols, products and techniques for clinical-grade cell processing and manufacturing. Cell processing devices, cultureware, bioreactors, GMP-grade reagents, cell separation techniques. This series is posted every 2 months.


Validation of fully automated device Stempeutron for isolation of adipose tissue-derived SVF (Stem Cells Int) FREE

Cell composition included CD34+CD31− adipose stromal cells, CD34+CD31+ endothelial progenitor cells, and CD34−CD31+ endothelial cells, and their relative percentages were equivalent to SVF isolated by the manual method. CFU-F capacity and expression of angiogenic factors were also comparable with the manual method, establishing proof-of-concept for fully automated SVF isolation, suitable for use in reconstructive surgeries and regenerative medicine applications.

Validation of XcytePLUS xeno-free media platelet lysate supplement for expansion of MSCs (J Transl Med) FREE

These data support the implementation of human platelet lysate supplemented media as an alternative to xenogeneic containing preparations which may lead to safer MSC products with therapeutic uses.

Pre-clinical study of Pall Celeris device for enrichment of cells with angiogenic potential from peripheral blood (Cytotherapy) FREE

The Pall Celeris system may represent a novel, effective and reliable point-of-care device to obtain a PB-derived cell product with adequate potency for therapeutic angiogenesis.

1. Validation of WSCFD Stem Cell Thawer versus 37 °C thermostatic bath for thawing HPC-A products (Transfus Apher Sci)

WSCFD® can replace the 37 °C thermostatic bath thawing procedure for leukapheresis, providing more security and fully traceable process data.

2. GMP-compliant protocol for large-scale isolation of T-regs (J Immunother)

We developed a novel approach to isolate “untouched” human Treg cells from healthy donors on the basis of negative selection using the surface markers CD49d and CD127. This procedure, which uses an antibody cocktail and magnetic beads for separation in an automated system (RoboSep), was scaled up and adapted to be compatible with good manufacturing practice conditions. With this setup we performed 9 Treg isolations from large-scale leukapheresis samples in a good manufacturing practice facility. These runs yielded sufficient numbers of “untouched” Treg cells for immediate use in clinical applications.

3. Validation of Synthemax II and Enhanced Attachment microcarriers for xeno-free expansion of MSC in bioreactor (Biotechnol J)

This culture system yielded considerable final cell densities that can be scaled-up to controlled large-scale bioreactors allowing a more efficient, safe and cost-effective MSC production for clinical settings.

4. Protocol for rapid generation of NY-ESO-1-specific T-cells for adoptive T-cell therapy (Oncoimmunology)

Here, we report a procedure to generate cancer-testis antigen NY-ESO-1-targeting CD4+ TH1 cells in vitro for cancer immunotherapy in the clinic. After in vitro sensitization by stimulating T cells with protein-spanning, overlapping peptide pools of NY-ESO-1 in combination with IL-7 and low dose IL-2, antigen-specific T cells were isolated using IFNγ capture technique and subsequently expanded with IL-2, IL-7 and IL-15.

5. Validation of closed system Cell-Max cryobags for cryopreservation of HPC-A products (Transfusion)

Our data confirm that cryopreservation of PBSCs within a functionally closed-bag system is safe, effective, and economical. Furthermore, the system has the potential to be extended to other manufacturing processes of cellular products.

6. Low-cost generation of GMP–grade CD19-CAR T-cells using piggyBac gene transfer (Cytotherapy)

We have produced a simple, inexpensive and easily adoptable protocol for the generation of CAR19 T cells suitable for use in clinical trials using the piggyBac transposon system. This provides a robust platform for further enhancing the T-cell product and testing new CAR technologies.

7. Clinical-scale isolation of Aspergillus fumigatus–reactive T–cells with CD137 magnetic beads (Cytotherapy)

We developed a Good Manufacturing Practice (GMP)-compliant protocol for preparation of A. fumigatus–specific CD4+ cells by sequentially depleting regulatory and cytotoxic T cells, activating A. fumigatus-specific T-helper cells with GMP-grade A. fumigatus lysate, and immuno-magnetically isolating them via the transiently up-regulated activation marker, CD137.

8. Validation of GMP-compliant SmyleDCpp65 lentivirus-induced dendritic cells system (J Transl Med) FREE

Upscaling and standardized production of one lot of IDLV and three lots of SmyleDCpp65 under GMP-compliant conditions were feasible. Analytical parameters for quality control of SmyleDCpp65 identity after thawing and potency after culture were defined. Cell recovery, uniformity, efficacy of gene transfer, purity and viability were high and consistent. SmyleDCpp65 showed only residual and polyclonal IDLV integration, unbiased to proto-oncogenic hot-spots. Stimulation of autologous T cells by GMP-grade SmyleDCpp65 was validated.

{ 0 comments… add one now }

Leave a Comment

Previous post:

Next post: